Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

Autor: Chitnis, T, Arnold, Dl, Banwell, B, Brück, W, Ghezzi, A, Giovannoni, G, Greenberg, B, Krupp, L, Rostásy, K, Tardieu, M, Waubant, E, Wolinsky, Js, Bar-Or, A, Stites, T, Chen, Y, Putzki, N, Merschhemke, M, Gärtner, Collaborators (85): Kornberg A, J, Bajer-Kornek, B, Likhachev, S, Pereira Gomes Neto, A, Diniz, D, Paz, J, Alvarenga, R, Bojinova-Tchamova, V, Mah, J, Venkateswaran, S, Hafner, K, Gross-Paju, K, Brochet, B, Cheuret, E, Rivier, F, Deiva, K, Milh, M, Blaschek, A, Trollmann, R, Korinthenberg, R, Luecke, T, Ziemssen, T, Pozzilli, C, Patti, F, Comi, G, Marfia, G, Grimaldi, L, Trojano, M, Zaffaroni, M, Capra, R, Brescia Morra, V, Rozentals, G, Laurynaitiene, J, Vaiciene-Magistris, N, Castro Farfan, F, Quinones, S, Steinborn, B, Ujma-Czapska, B, Stasiolek, M, Jasinski, M, Craiu, D, Boyko, A, Kairbekova, E, Khabirov, F, Kuzenkova, L, Malkova, N, Nikolic, D, Jancic, J, Gebauer-Bukurov, K, Payerova, J, Gascon Jiménez, F, Izquierdo Ayuso, G, Mendibe Bilbao, M, Hintzen, R, Fernandez Sanchez VE, Meca Lallana, V, Montalban Gairin, X, Nordborg, K, Anlar, B, Yalcinkaya, C, Gucuyener, K, Terzi, M, Ozakbas, S, Yilmaz, U, Makedonska, I, Prokopenko, K, Tantsura, L, Moskovko, S, Kobys, T, Muratova, T, Nehrych, T, Prykhodko, T, Hemingway, C, Wassmer, E, Shetty, J, Desai, J, Waldman, A, Chinea Martinez, A, Ness, J, Rammohan, K, Lloyd, M, Williams, M, Ayala, R, Davis, R, Bhise, V
Přispěvatelé: Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), McConnell Brain Imaging Centre (MNI), Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada]-McGill University = Université McGill [Montréal, Canada], University of Pennsylvania [Philadelphia], Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
[SDV]Life Sciences [q-bio]
Administration
Oral
administration
oral
adolescent
brain
child
female
fingolimod hydrochloride
headache
humans
immunologic factors
infection
injections
intramuscular
interferon-beta
leukopenia
magnetic resonance imaging
male
multiple sclerosis
relapsing-remitting
secondary prevention
medicine (all)
law.invention
0302 clinical medicine
Randomized controlled trial
Interferon
law
Medicine
Secondary prevention
General Medicine
Fingolimod
3. Good health
Settore MED/26 - Neurologia
medicine.drug
medicine.medical_specialty
Infections
Injections
Intramuscular
Adolescent
Brain
Child
Female
Fingolimod Hydrochloride
Headache
Humans
Immunologic Factors
Infection
Interferon-beta
Leukopenia
Magnetic Resonance Imaging
Male
Multiple Sclerosis
Relapsing-Remitting
Secondary Prevention
03 medical and health sciences
Internal medicine
business.industry
Multiple sclerosis
Interferon beta-1a
medicine.disease
Clinical trial
030104 developmental biology
Multicenter study
business
030217 neurology & neurosurgery
Zdroj: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (11), pp.1017--1027. ⟨10.1056/NEJMoa1800149⟩
ISSN: 0028-4793
1533-4406
DOI: 10.1056/NEJMoa1800149⟩
Popis: International audience; BACKGROUND: Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. METHODS: In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body weight of
Databáze: OpenAIRE
Externí odkaz: